Loading clinical trials...
Loading clinical trials...
A Phase II, Randomized, Double-Blind, Dosage, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Combined With Aluminum Hydroxide Adjuvant in Children, Toddlers, and Infants
Conditions
Interventions
GI.1/GII.4 (15/15)
GI.1/GII.4 (15/50)
+3 more
Locations
12
Colombia
Centro de Estudios em Infectologia Pediatrica SAS
Cali, San Fernando, Colombia
Espoon Rokotetutkimusklinikka
Espoo, Finland
Etela-Helsingin Rokotetutkimusklinikka
Helsinki, Finland
Ita-Helsingin Rokotetutkimusklinikka
Helsinki, Finland
Jarvenpaan Rokotetutkimusklinikka
Jarvenpaan, Finland
Oulun Rokotetutkimusklinikka
Oulu, Finland
Start Date
June 23, 2015
Primary Completion Date
June 20, 2018
Completion Date
June 20, 2018
Last Updated
April 1, 2019
NCT06944717
NCT07254728
NCT06568380
NCT04875676
NCT06211621
NCT04941261
Lead Sponsor
Takeda
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions